The Food and Drug Administration granted priority review to Pfizer’s RSV vaccine. The pharma giant is seeking approval for use of the vaccine, RSVpreF, in adults aged 60 years and older and the agency is set to make its decision by May 2023. (Reuters)

Prometheus Biosciences reported positive results from a pair of studies of its lead product candidate PRA023 in inflammatory bowel diseases. The San Diego clinical-stage biotech company said PRA023 showed strong efficacy and favorable safety results in Phase 2 and Phase 2a studies. (MarketWatch)

Juul reached settlements covering more than 5,000 cases. The electronic cigarette maker has reached settlements covering more than 5,000 cases brought by about 10,000 plaintiffs related to its vaping products. (ABC News)

GSK shares surged as a U.S. judge dismissed Zantac cancer claims. The ruling can still be appealed against, and the decision does not directly affect tens of thousands of similar cases pending in state courts around the country. (The Guardian)

Extreme training techniques have pushed bodybuilders to take steroids and other drugs, resulting in severe injury or death. A review of hundreds of documents including medical and autopsy records, police reports, 911 calls, emails and text messages reveals the devastating consequences of a sport that for years has operated under the halo of health and fitness. (The Washington Post)